IPO Year: 2021
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/16/2024 | $14.00 | Buy | Alliance Global Partners |
6/13/2024 | $13.00 | Buy | Rodman & Renshaw |
10/16/2023 | $4.00 | Buy | B. Riley Securities |
10/13/2023 | $4.00 | Buy | B. Riley Securities |
10/9/2023 | $12.00 | Buy | H.C. Wainwright |
PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today reported that it received a notice (the "Notice") on November 21, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter
PALO ALTO, Calif. , Nov. 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced presentation of data at the 2024 American College of Rheumatology Convergence conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024. Title: Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model
NEW YORK, NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from November 11, 2024, to December 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing o
As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator
Successful end of Phase II meeting with FDA leading to an agreed path forward to NDA upon completion of Phase III trials for blockbuster product candidate, SP-103, for the treatment of chronic neck pain associated with muscle spasms.SP-103 (lidocaine topical system) 5.4%, ("SP-103"), a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain. It is estimated that the U.S. low back and neck pain market will reach $134.5 billion.6 Based on the independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-103 with peak sales potential projected to reach $1.2 billion annually in the 6th year p
Scilex management is determined to enhance its stockholders' value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock.Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex. Such record date may be changed by Scilex's board of directors for any reason at any time prior to the actual payment of such dividend of Scilex preferred stock. No payment date has been set for the payment of such dividend and such payment is conditioned upon the Scilex board of director
Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with
Scilex Holding Company seeks to maximize the value of its stockholders, including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals ("Scilex Pharma") in markets and on securities exchanges in or outside of the U.S., including Hong Kong.Scilex Holding Company management believes the potential value of Scilex Pharma may exceed the current valuation of its parent company, Scilex Holding Company, and that a potential spinoff or public listing of Scilex Pharma would serve to unlock the potential value of Scilex Pharma and its parent, Scilex Holding Company. Also a potential strategic transaction and/or dividend of Scilex Pharma common stock to Scilex Holding
Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile
NEW YORK, NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from October 11, 2024, to November 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing
424B3 - Scilex Holding Co (0001820190) (Filer)
424B3 - Scilex Holding Co (0001820190) (Filer)
8-K - Scilex Holding Co (0001820190) (Filer)
424B3 - Scilex Holding Co (0001820190) (Filer)
424B3 - Scilex Holding Co (0001820190) (Filer)
8-K - Scilex Holding Co (0001820190) (Filer)
8-K - Scilex Holding Co (0001820190) (Filer)
8-K/A - Scilex Holding Co (0001820190) (Filer)
424B3 - Scilex Holding Co (0001820190) (Filer)
424B3 - Scilex Holding Co (0001820190) (Filer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
ACEA Therapeutics ("ACEA") will serve as exclusive territories distributor in Greater China, including mainland China, Taiwan, Hong Kong and Macau, with potential minimum purchase commitment for ZTlido once approved locally in the region.ACEA to immediately start the process to explore potential commercialization of ZTlido®, with the opportunity to distribute with partners across Greater China and further expand the relationship to include other products in Scilex's non-opioid pain portfolio.PALO ALTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))))), an innovative revenue-generating company focused on acquiring, developing and com
Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company (NASDAQ:SCLX), and Denali Capital Acquisition Corp. (NASDAQ:DECA), a special purpose acquisition company, signed a letter of intent for a proposed business combination. The deal provides for a pre-transaction equity value of Semnur up to $2 billion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares redeemed before the business combination is completed. Semnur is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies. Semnur’s lead program, SP-102 (SEMDEXA), is the first non-opioid novel injectab
Scilex is expected to be the majority holder of the combined company following completion of the proposed business combination.
June closed on a high note for the stock market, with the S&P 500, tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY), gaining 3.2%, despite significant disparities in sector and industry performances. The technology sector, as tracked by the Technology Select Sector SPDR Fund (NYSE:XLK), led the 11 S&P 500 sectors in performance last month, surging 7.7% and achieving its strongest monthly gain this year. In stark contrast, utilities lagged, with the Utilities Select Sector SPDR Fund (NYSE:XLU) dropping 6.3%, marking the worst month since September 2023. Top Performing Industry ETFs In June The iShares Expanded Tech-Software Sector ETF (NYSE:IGV) rallied 11.3% last month, topping
On June 17, 2024, the Board of Directors of Scilex Holding Company (the "Company") approved a resolution to authorize management to explore ways in which to maximize the value of Semnur Pharmaceuticals, Inc. ("Semnur"), the Company's wholly owned subsidiary, and SP-102 (SEMDEXA™), the product candidate held by Semnur, for the Company and its stockholders, including by way of conducting a spin-off, merger, dividend, reclassification or other similar transaction.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Scilex Holding (NASDAQ:SCLX) with a Buy and maintains $7 price target.
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
Alliance Global Partners initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $14.00
Rodman & Renshaw initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $13.00
B. Riley Securities initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $4.00
B. Riley Securities initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $4.00
H.C. Wainwright initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $12.00
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has added to its Board of Directors a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care, Annu Navani, M.D. Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over th
PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the launch of its redesigned website showcasing the Company's growing portfolio of non-opioid pain management therapeutics. The new website can be accessed by visiting www.scilexholding.com, The features of the new and improved website include: Sleek, modern web design with dynamic elements and illustrations;An overview of the Company's science and expanded product portfolio and pr
SC 13D/A - Scilex Holding Co (0001820190) (Subject)
SC 13D/A - Scilex Holding Co (0001820190) (Subject)
As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator
Scilex management is determined to enhance its stockholders' value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock.Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex. Such record date may be changed by Scilex's board of directors for any reason at any time prior to the actual payment of such dividend of Scilex preferred stock. No payment date has been set for the payment of such dividend and such payment is conditioned upon the Scilex board of director
Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with
Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile
US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to January 31, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to January 31, 2025. PALO ALTO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management p
Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dexam
Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))) announce the signing of an agreement and plan of merger for a proposed business combination (the "Business Combination Agreement"), which provides for a pre-transaction equity value of Semnur of $2.5 billion. The Board of Scilex, Semnur, and Denali Capital Acquisition Corp. have approved the proposed transaction. The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for the development of a non-opioid product, SP-102 (10 mg injectable dex
Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), and Denali Capital Acquisition Corp. (NASDAQ:DECA) ("SPAC") announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur of up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected cash on hand at closing of up to $40 million depending on the number of SPAC shares that are redeemed prior to the completion of the business combination.The proposed business combination would create a publicly traded biopharma company and further provide investment into Semnur for th
PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and highly respected distributor with over 10 years of sales excellence, Endeavor Distribution LLC. ("Endeavor"). Endeavor has logistics expertise to sell and distribute our currently marketed non-opi
Scilex management is determined to enhance its stockholders' value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock.Of the approximately 181 million shares of Scilex common stock currently issued and outstanding: (a) 76 million were distributed by Sorrento Therapeutics, Inc. (OTC:SRNEQ, "Sorrento"))) as dividend shares in January 2023 (the "Dividend Shares") and are restricted from trading until the earlier of (i) September 30, 2024 per court order or (ii) the date on which Sorrento and its Official Committee of Unsecured Creditors agree in writing or on the record in Sorrento's chapter 11 cases certain